Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1347-1350

  Amengual, Jennifer E ^a   Raphael, Bruce G ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BEVACIZUMAB; CARBOPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; THALIDOMIDE; VALGANCICLOVIR; VINCRISTINE;

ADULT; AGED; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CHEMOTHERAPY; CLONAL VARIATION; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE REARRANGEMENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOHISTOCHEMISTRY; LEGIONELLA; LETTER; LYMPH NODE CELL; LYMPHADENOPATHY; LYMPHOCYTE; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; PLASMA CELL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLENOMEGALY; SURVIVAL TIME; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77954107956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.486091     Document Type: Letter

References (16)

1. Mourad N, Mounier N, Brieve J, et al. Clinical, biologic and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008;111: 4463-4470.
2. Dogan A, Attygalle A, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003;121:681-691.
3. Grogg K, Morice W, Macon W. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 2007;137:416-422.
4. Zhou Y, Attygalle AD, Chuang S, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007;138:44-53.
5. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. 1998;92:78-82.
6. Park B, Ryoo B, Lee J, et al. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007;48:716-722.
7. Pautier P, Devidas A, Delmer A, et al. Angioimmunoblasticlike T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999;32:545-1522
8. Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G. Complete remission in a patient with a relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;12:1993-1995.
9. Takemori N, Kodairi J, Toyoshima N, et al. Successful treatment of immunoblastic lymphadenopathy-like T-cell lymphoma with cyclosporin A. 1999;35:389-395.
10. Strupp C, Aivada M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002;43:133-137.
11. Hast R, Jacobsson B, Petrescu A, Hjalmar V. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 1999;34:597-601.
12. Advani R, Horwitz S, Zelenetz A, Horning S. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521-525.
13. Chang S, Lu C, Chuang S. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007;48: 117-121.
14. Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm 2004;19:391-398.
15. Halene S, Zieske A, Berliner N. Sustainted remission from angioimmunoblastic T-cell lymphoma induced by alentuzumab. Nat Clin Pract Oncol 2006;3:165-168.
16. O'Connor O, Pro B, Pinter-Brown L, et al. PROPEL: results of the pivotal multicenter phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol 2009;27(Suppl.):15s (Abstract 8561).